 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...484485486487488489490491492493494...507508» |
- Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 11, 2014
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Sep 2016
- | Enrollment open: International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma (clinicaltrials.gov) - Sep 11, 2014
P2/3, N=360, Recruiting, Sponsor: Universit
Trial primary completion date: Sep 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- zoledronic acid / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases (clinicaltrials.gov) - Sep 11, 2014
P2, N=80, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2014
- |||| Rituxan (rituximab) / Roche
Trial primary completion date, IO biomarker, Metastases: Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients (clinicaltrials.gov) - Sep 10, 2014
P3, N=210, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- |||| Trial primary completion date, IO biomarker, Surgery: ARST0332: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 9, 2014
P3, N=588, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2012 --> Sep 2014
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial initiation date: TRIUMPH: TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen (clinicaltrials.gov) - Sep 9, 2014
P2, N=45, Not yet recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: Feb 2012 --> Sep 2014 Initiation date: Feb 2014 --> Oct 2014
- | Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open, Combination therapy: Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ (clinicaltrials.gov) - Sep 9, 2014
P3, N=250, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Initiation date: Feb 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche
Trial primary completion date: Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas (clinicaltrials.gov) - Sep 8, 2014
P2, N=52, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- || Rituxan (rituximab) / Roche
Trial primary completion date: Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger (clinicaltrials.gov) - Sep 5, 2014
P2, N=66, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- | melphalan / Generic mfg., busulfan / Generic mfg.
Trial suspension, Trial primary completion date: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=160, Suspended, Sponsor: Children's Oncology Group
Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Suspended | Trial primary completion date: Jan 2015 --> Oct 2014
- Trial primary completion date: neo-TN: Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 4, 2014
P2/3, N=270, Recruiting, Sponsor: The Netherlands Cancer Institute
Active, not recruiting --> Suspended | Trial primary completion date: Jan 2015 --> Oct 2014 Trial primary completion date: Jan 2015 --> Dec 2015
- | Trial initiation date, Metastases: High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (clinicaltrials.gov) - Sep 4, 2014
P3, N=86, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Jan 2015 --> Dec 2015 Initiation date: Jul 2012 --> Sep 2014
- carboplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Jul 2012 --> Sep 2014 Trial primary completion date: Oct 2014 --> Oct 2015
- Trial termination, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=7, Terminated, Sponsor: City of Hope Medical Center
Trial primary completion date: Oct 2014 --> Oct 2015 Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor.
- | New P1/2 trial: Vaccination of High Risk Breast Cancer Patients (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=61, Not yet recruiting, Sponsor: University of Arkansas
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=46, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Ninlaro (ixazomib) / Takeda
New P1 trial: Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - Aug 29, 2014
P1, N=28, Not yet recruiting, Sponsor: Massachusetts General Hospital
- |||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer (clinicaltrials.gov) - Aug 27, 2014
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor. Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014
- || Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 26, 2014
P1/2, N=146, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014 Trial primary completion date: Mar 2014 --> Aug 2014
- | Arzerra (ofatumumab) / Novartis, Genmab
Enrollment change, Combination therapy: NCI-2011-03562: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 26, 2014
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Mar 2014 --> Aug 2014 N=53 --> 37
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial initiation date, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Aug 23, 2014
P3, N=216, Ongoing, Sponsor: EORTC
N=53 --> 37 Initiation date: Jun 2012 --> Mar 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Aug 22, 2014
P2, N=28, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Jun 2012 --> Mar 2013 Trial primary completion date: Dec 2014 --> Dec 2015
- | Istodax (romidepsin) / Astellas, BMS
New P1/2 trial, Combination therapy: PTCL13: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (clinicaltrials.gov) - Aug 22, 2014
P1/2, N=110, Active, not recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
- ||| Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Roche
Metastases: Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (clinicaltrials.gov) - Aug 22, 2014
P2, N=97, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial termination: Dose-adjusted EPOCH-R in MYC Positive DLBCL (clinicaltrials.gov) - Aug 21, 2014
P2, N=26, Terminated, Sponsor: Fudan University
Completed --> Active, not recruiting Recruiting --> Terminated; Poor accrual of eligible patients
- || doxorubicin hydrochloride / Generic mfg.
Enrollment closed: MIRACLE I: Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: CeloNova BioSciences, Inc.
Recruiting --> Terminated; Poor accrual of eligible patients Recruiting --> Active, not recruiting
- |||| Trial primary completion date, IO biomarker, Surgery: ARST0332: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 19, 2014
P3, N=588, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2100 --> Feb 2012
- || melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=138, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2100 --> Feb 2012 Recruiting --> Active, not recruiting
- Beleodaq (belinostat) / Aurobindo, Assertio
Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (clinicaltrials.gov) - Aug 15, 2014
P1/2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change, Trial termination: SPI-ZEV-11-301: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy (clinicaltrials.gov) - Aug 15, 2014
P3, N=81, Terminated, Sponsor: Spectrum Pharmaceuticals, Inc
Trial primary completion date: Dec 2014 --> Jun 2015 N=490 --> 81 | Recruiting --> Terminated
- Halaven (eribulin mesylate) / Eisai
New P2 trial: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=30, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- lenalidomide / Generic mfg.
Enrollment open: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (clinicaltrials.gov) - Aug 15, 2014
P1/2, N=46, Recruiting, Sponsor: University of Chicago
N=490 --> 81 | Recruiting --> Terminated Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=184, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche
Enrollment closed, Metastases: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 15, 2014
P1/2, N=96, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Biomarker, Trial completion, Trial primary completion date: LNH2007-3B: A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma (clinicaltrials.gov) - Aug 15, 2014
P2, N=222, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2013
- || brivanib alaninate (BMS-582664) / ZAI Lab
Trial primary completion date, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Aug 12, 2014
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2013 Trial primary completion date: Feb 2015 --> Sep 2014
- | epirubicin / Generic mfg.
New P4 trial: NMIBCIVT: Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 12, 2014
P4, N=240, Recruiting, Sponsor: Mansoura University
- ||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
New P2 trial: A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response (clinicaltrials.gov) - Aug 12, 2014
P2, N=300, Active, not recruiting, Sponsor: West German Study Group
- lenalidomide / Generic mfg.
New P1/2 trial: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (clinicaltrials.gov) - Aug 12, 2014
P1/2, N=46, Not yet recruiting, Sponsor: University of Chicago
- | sunitinib / Generic mfg.
Trial completion: Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=23, Completed, Sponsor: Indiana University
Trial primary completion date: Feb 2015 --> Sep 2014 Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date: A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin (clinicaltrials.gov) - Aug 11, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: May 2016 --> Sep 2016
- |||||| Enrollment open: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma (clinicaltrials.gov) - Aug 11, 2014
P3, N=803, Recruiting, Sponsor: Children's Oncology Group
Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: May 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 8, 2014
P2, N=22, Active, not recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Apr 2015
- |||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2014
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2014 --> Apr 2015 Trial primary completion date: Oct 2012 --> Jun 2014
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P2b, N=133, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Oct 2012 --> Jun 2014 N=370 --> 133
- ||||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment closed, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=1164, Active, not recruiting, Sponsor: Children's Oncology Group
N=370 --> 133 Completed --> Active, not recruiting
- | Granocyte (lenograstim) / Roche
Trial completion, Surgery: EORTC-STBSG 62931: Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=350, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Completed --> Active, not recruiting Active, not recruiting --> Completed
- |||||| olanzapine / Generic mfg.
Enrollment open, Trial initiation date, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Aug 7, 2014
P3, N=372, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (clinicaltrials.gov) - Aug 7, 2014
P2, N=45, Active, not recruiting, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- || Xalkori (crizotinib) / Pfizer
Enrollment closed, Trial primary completion date, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Aug 7, 2014
P1, N=58, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Aug 2014